



Looking Beyond CBD: Researchers Investigate CBDA and Other Cannabinoids

Cannabinoid research is gradually moving beyond the familiar discussion of CBD and THC.

A 2026 clinical study investigated different cannabinoid formulations in people living with fibromyalgia, rheumatoid arthritis and osteoarthritis. One of the formulations contained the non-intoxicating cannabinoids CBD and CBDA, while other formulations allowed researchers to examine broader cannabinoid combinations.

Improvements were observed across many of the measured symptoms, including pain, sleep and quality-of-life measures, although cognitive functioning did not improve. Because of limitations in the study design and participant attrition, the findings should be regarded as exploratory rather than definitive evidence of efficacy.

Potential application

The study is interesting because cannabinoid research is increasingly examining individual minor cannabinoids and combinations rather than treating "cannabis" as though it were a single substance. CBDA, CBG, CBC and other cannabinoids may ultimately prove to have distinctly different biological profiles.

Reference

Kruger DJ, Dautrich T, Hall B, Keeling K, Provost K, Boehnke KF. Assessing the efficacy of cannabinoid compositions for treating 3 classes of chronic pain: a real-world evidence study. *Clinical Therapeutics*. 2026;48(9):907–912.

Dr. Peter Verdegem, Ph.D., MBA

